Literature DB >> 20189773

Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia.

Xiaoduo Fan1, Emily Y Liu, Oliver Freudenreich, Ju Hyung Park, Dengtang Liu, Jijun Wang, Zhenghui Yi, Donald Goff, David C Henderson.   

Abstract

BACKGROUND: Unequivocal evidence has emerged linking inflammation to the risk of metabolic problems. Previous research also has suggested a relationship between inflammation and schizophrenia. The present study examined whether white blood cell count (WBC), a marker of systemic inflammation, is associated with metabolic syndrome and psychiatric symptoms in non-diabetic patients with schizophrenia.
METHODS: Outpatients 19 to 75 years old diagnosed with schizophrenia or schizoaffective disorder participated in a multi-center, cross-sectional study. Vital signs and anthropometric measures were obtained. Fasting blood samples were collected to determine levels of glucose, lipids and WBC. Psychiatric symptoms were assessed using the Brief Psychiatric Rating Scale (BPRS).
RESULTS: In the sample of 199 patients, multiple logistic regression showed that WBC (log transformed) strongly predicted the condition of metabolic syndrome after potential confounding variables including age, gender, race, age of illness onset, family history of diabetes, smoking status and antipsychotic agent used were taken into consideration (odds ratio 47.2, 95% CI 3.4-658.7, p=0.004). On the other hand, significant correlations were found between WBC (log transformed) and BPRS-total score (r=0.18, p=0.014), negative symptom score (r=0.15, p=0.039) as well as anxious depression factor score (r=0.21, p=0.004) after potential confounding variables were taken into consideration.
CONCLUSION: This study suggested that WBC, a simple, readily available and inexpensive measure, may potentially be a useful marker to predict an increased risk for metabolic syndrome and more severe psychiatric symptoms in non-diabetic patients with schizophrenia. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189773     DOI: 10.1016/j.schres.2010.02.1028

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  25 in total

Review 1.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

2.  Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study.

Authors:  Yanli Luo; Fang Liu; Radhika Natarajan; Nawras Shukair; Paul Copeland; Xiaoduo Fan
Journal:  Int Clin Psychopharmacol       Date:  2018-03       Impact factor: 1.659

3.  A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.

Authors:  Brenda Vincenzi; Shannon Stock; Christina P C Borba; Sarah M Cleary; Claire E Oppenheim; Liana J Petruzzi; Xiaoduo Fan; Paul M Copeland; Oliver Freudenreich; Corinne Cather; David C Henderson
Journal:  Schizophr Res       Date:  2014-09-26       Impact factor: 4.939

4.  Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.

Authors:  A Zarina Kraal; Kristen M Ward; Vicki L Ellingrod
Journal:  Psychopharmacol Bull       Date:  2017-05-15

5.  Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia: implications for the role of inflammation.

Authors:  Kosuke Kajitani; Kazuyuki Yanagimoto; Yusaku Nakabeppu
Journal:  Psychopharmacology (Berl)       Date:  2017-07-11       Impact factor: 4.530

Review 6.  The Gut-Brain Axis, BDNF, NMDA and CNS Disorders.

Authors:  Raeesah Maqsood; Trevor W Stone
Journal:  Neurochem Res       Date:  2016-08-23       Impact factor: 3.996

7.  Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses.

Authors:  Brian J Miller; Prianka Kandhal; Mark Hyman Rapaport; Andrew Mellor; Peter Buckley
Journal:  Brain Behav Immun       Date:  2014-12-24       Impact factor: 7.217

8.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

9.  The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.

Authors:  X Fan; X Song; M Zhao; L F Jarskog; R Natarajan; N Shukair; O Freudenreich; D C Henderson; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2017-08-29       Impact factor: 6.392

10.  Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses.

Authors:  Brian J Miller; Andrew Mellor; Peter Buckley
Journal:  Brain Behav Immun       Date:  2012-09-11       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.